Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

Donald Trump is executing a shock-and-awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in the courts. Some, ...

The right-wing argues, as Project 2025 puts it, that government negotiations on Medicare drugs amount to “price controls” that will reduce patient access to new medication. That’s news to the citizens ...